GO:0051897 positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051897 describes any process that activates or increases the frequency, rate or extent of phosphatidylinositol 3-kinase/protein kinase B signal transduction.
• The PI3K/AKT pathway is a central signaling axis that controls cell growth, survival, metabolism, and immune responses.
• Positive regulation of this pathway often involves growth factor receptor activation, PTEN inactivation, or direct mutations in PIK3CA and AKT1.
• Dysregulation of PI3K/AKT signaling is implicated in cancer, metabolic disorders, cardiovascular disease, and inflammation.
• Key experimental models include knockout, point-mutation knock-in, and overexpression cell lines to dissect pathway components.
• CRISPR-based screens and bioinformatics are powerful tools to identify novel regulators of GO:0051897.
Description
The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling cascade is one of the most frequently deregulated pathways in human disease. GO:0051897, positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction, encompasses all molecular events that enhance the activity of this pathway. Understanding how this process is controlled is essential for researchers studying cancer, metabolism, immunity, and cardiovascular biology. This article provides a comprehensive overview of the ontology term, its mechanistic basis, key genes, disease relevance, and state-of-the-art research methods, including CRISPR-based models.
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction At A Glance
| GO ID | GO:0051897 |
|---|---|
| GO term | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
| Ontology | biological_process |
| Synonym | positive regulation of PI3K/Akt signal transduction; activation of protein kinase B signaling cascade; upregulation of protein kinase B signaling cascade |
| Major function | Enhances PI3K/AKT signaling, promoting cell growth, survival, proliferation, and metabolism |
| Related pathways | Growth factor receptor signaling, insulin signaling, immune cell activation |
| Key regulators | PIK3CA, AKT1, PTEN, mTOR, RTKs |
| Disease relevance | Cancer, diabetes, cardiovascular disease, inflammation |
What Is GO:0051897?
GO:0051897 is a biological process term defined as any process that activates or increases the frequency, rate or extent of phosphatidylinositol 3-kinase/protein kinase B signal transduction. In simpler terms, it covers all the ways cells boost the PI3K/AKT signaling pathway, which transmits growth and survival signals from the cell surface to downstream effectors.
Why Is positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction Important in Cell Biology?
GO:0051897 is critically important because the PI3K/AKT pathway is a master regulator of fundamental cellular processes, and its positive regulation is often hijacked in disease. For example, activating mutations in PIK3CA or loss of PTEN lead to constitutive pathway activation in many cancers. In metabolic disorders, enhanced PI3K/AKT signaling in specific tissues can improve glucose homeostasis. Thus, understanding the mechanisms that positively regulate this pathway is essential for developing targeted therapies.
• Drives cancer cell proliferation and survival when hyperactivated.
• Mediates insulin signaling and glucose uptake, relevant to diabetes.
• Regulates immune cell function, including T cell immunity.
• Protects cardiomyocytes from apoptosis and ferroptosis.
• Modulates inflammatory responses in macrophages.
• Involved in skin disorders such as psoriasis.
• Plays a role in β-cell function and stress responses.
• Serves as a target for drug discovery, e.g., PI3K inhibitors.
• Key for understanding developmental processes and tissue homeostasis.
• Enables CRISPR screening to identify novel pathway regulators.
What Happens During positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction?
Receptor Activation and PI3K Recruitment
In simple terms: Growth factors bind to receptors on the cell surface, which then activate PI3K inside the cell.
Positive regulation often begins with the binding of growth factors or cytokines to receptor tyrosine kinases (RTKs) or G-protein-coupled receptors. This binding induces receptor dimerization and autophosphorylation, creating docking sites for the p85 regulatory subunit of PI3K. Recruitment of the p85-p110 complex to the membrane leads to PI3K activation. Additionally, the protein tyrosine phosphatase Shp2 can modulate PI3K activation in a receptor-specific manner.
PIP3 Generation and AKT Membrane Recruitment
In simple terms: Activated PI3K produces a lipid signal that recruits AKT to the cell membrane.
Activated PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 serves as a second messenger that recruits pleckstrin homology (PH) domain-containing proteins, including AKT and PDK1, to the plasma membrane. This step is antagonized by PTEN, a lipid phosphatase that converts PIP3 back to PIP2, thereby acting as a negative regulator of the pathway.
AKT Phosphorylation and Full Activation
In simple terms: Once at the membrane, AKT gets phosphorylated and becomes fully active.
At the membrane, PDK1 phosphorylates AKT at Thr308, and mTORC2 phosphorylates AKT at Ser473, leading to full AKT activation. Activated AKT then phosphorylates numerous downstream substrates, such as TSC2, FOXO, and GSK3, to promote cell growth, survival, and metabolism. Positive regulation of this step can occur through enhanced PIP3 production or increased mTORC2 activity.
Metabolic Amplification by Glycolysis
In simple terms: Cellular metabolism, especially glycolysis, can further boost PI3K signaling.
Recent studies have shown that glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity. Glycolytic enzymes can interact with and enhance PI3K activity, creating a positive feedback loop that sustains AKT signaling. This highlights the interplay between metabolism and GO:0051897.
Downstream Effector Activation and Cellular Outcomes
In simple terms: Active AKT turns on many proteins that make cells grow, survive, and proliferate.
Activated AKT phosphorylates a wide array of downstream effectors, including mTOR, which promotes protein synthesis and cell growth; FOXO transcription factors, which are inhibited to prevent apoptosis; and GLUT1, which enhances glucose uptake. These events collectively mediate the cellular outcomes of positive regulation of PI3K/AKT signaling, such as survival, proliferation, and metabolic reprogramming.
Key Genes Involved in GO:0051897 positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
The following genes and proteins are central to the positive regulation of PI3K/AKT signaling (GO:0051897).
| Gene | Major Role | Research Relevance |
|---|---|---|
| PIK3CA | Encodes p110α catalytic subunit of PI3K; activating mutations drive pathway | Oncogene, frequently mutated in cancers |
| PIK3R1 | Encodes p85α regulatory subunit; modulates PI3K activity | Tumor suppressor in some contexts |
| AKT1 | Serine/threonine kinase; key effector of PI3K signaling | Mutations linked to cancer and overgrowth syndromes |
| PTEN | Lipid phosphatase that dephosphorylates PIP3; negative regulator | Tumor suppressor; loss activates PI3K/AKT |
| mTOR | Kinase in mTORC1 and mTORC2; downstream of AKT and in complex 2 activates AKT | Target for immunosuppression and cancer therapy |
| PDK1 | Phosphorylates AKT at Thr308; essential for AKT activation | Kinase required for PI3K signaling |
| FOXO1 | Transcription factor inhibited by AKT; regulates apoptosis and metabolism | Downstream effector |
| GSK3B | Kinase inhibited by AKT; involved in metabolism and survival | Downstream target |
| TSC2 | Tuberin; inhibited by AKT, leading to mTORC1 activation | Links PI3K/AKT to mTOR |
| SHP2 (PTPN11) | Protein tyrosine phosphatase; regulates PI3K activation | Modulates RTK signaling |
| GLUT1 (SLC2A1) | Glucose transporter; upregulated by AKT to enhance glycolysis | Metabolic target |
| TFF3 | Trefoil factor family 3; upregulates PI3K/AKT in liver | Potential therapeutic target |
| FGF4 | Fibroblast growth factor 4; reduces M1 macrophage polarization via PI3K/AKT | Inflammation modulator |
| INSR | Insulin receptor; activates PI3K/AKT in response to insulin | Metabolic regulation |
| IGF1R | IGF-1 receptor; activates PI3K/AKT to promote growth | Cancer and growth disorders |
| RICTOR | Component of mTORC2; required for AKT Ser473 phosphorylation | Regulates AKT activation |
| RPTOR | Component of mTORC1; downstream of AKT | Regulates cell growth |
| PDPK1 | Same as PDK1; phosphorylates AKT | Kinase in pathway |
How Is positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction Regulated?
The positive regulation of PI3K/AKT signaling is tightly controlled by multiple mechanisms. Negative regulators include PTEN, which dephosphorylates PIP3, and SHIP phosphatases. Positive regulators include growth factor receptors, integrins, and oncogenic mutations in PIK3CA or AKT1. Additionally, mTORC2 phosphorylates AKT to sustain activation, and metabolic inputs such as glycolysis can amplify signaling. Cross-talk with other pathways, such as the Ras/MAPK pathway, also modulates PI3K/AKT activity.
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PIK3CA | Cancer (breast, colorectal, etc.) | Knock-in of activating mutations (e.g., H1047R) in cell lines |
| PTEN | Cancer, autism spectrum disorders | Knockout in cancer cell lines or organoids |
| AKT1 | Cancer, Proteus syndrome | Point mutation knock-in (E17K) in cell lines |
| TFF3 | Diabetes, liver disease | Overexpression in hepatocytes |
| FGF4 | Autoimmune hepatitis | Knockout or overexpression in macrophages |
Cancer
Hyperactivation of PI3K/AKT signaling is a hallmark of many cancers. Activating mutations in PIK3CA, loss of PTEN, and AKT1 mutations lead to constitutive pathway activation, promoting tumor growth and survival. Targeting this pathway with PI3K inhibitors is a major therapeutic strategy.
Metabolic Disorders
PI3K/AKT signaling is critical for insulin action and glucose homeostasis. In Zucker diabetic fatty rats, Roux-en-Y gastric bypass upregulates hepatic TFF3 and activates PI3K/AKT, improving liver and glucose homeostasis. Conversely, dysregulation contributes to insulin resistance and type 2 diabetes.
Cardiovascular Disease
In ischemic heart failure, modulation of PI3K/AKT signaling affects cardiomyocyte apoptosis and ferroptosis. Activation of this pathway by certain compounds can protect the heart. Dapagliflozin mitigates cellular stress and inflammation through PI3K/AKT modulation in cardiomyocytes and endothelial cells.
Inflammation and Autoimmune Conditions
FGF4 ameliorates liver inflammation by reducing M1 macrophage polarization via PI3K/AKT signaling. In psoriasis, inhibition of PI3K/AKT/GLUT1 signaling by quercetin reduces inflammation. Thus, positive regulation of PI3K/AKT can be either protective or pathogenic depending on context.
From positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a gene positively regulate PI3K/AKT signaling? | Knockout cell line followed by AKT phosphorylation assay |
| Does a specific mutation activate the pathway? | Point mutation knock-in (e.g., PIK3CA H1047R) |
| Does overexpression of a gene enhance signaling? | Overexpression cell line with doxycycline-inducible system |
| How does a gene affect pathway dynamics? | Tagged knock-in (e.g., GFP-AKT) for live imaging |
| What are novel regulators of the pathway? | CRISPR library screening (genome-wide KO or activation) |
| Does a drug modulate the pathway? | Pharmacological intervention in wild-type and mutant cells |
How to Study the positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Phospho-AKT levels | Pathway activation after treatment |
| CRISPR screen | Gene essentiality or reporter activation | Identify novel regulators |
| RNA-seq | Transcriptome changes | Downstream effects of pathway modulation |
| Live-cell imaging | AKT translocation or PIP3 dynamics | Real-time pathway activity |
| Co-immunoprecipitation | Protein-protein interactions | Identify pathway complexes |
| Flow cytometry | Phospho-AKT at single-cell level | Immune cell signaling |
| Metabolic assays | Glucose uptake or glycolysis | Metabolic outcomes of pathway activation |
Phospho-AKT Western Blotting
Measuring phosphorylation levels of AKT at Thr308 and Ser473 is a standard method to assess PI3K/AKT pathway activation. This is often used after genetic manipulation or drug treatment.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify positive regulators of PI3K/AKT signaling. Cells are selected for pathway activity using reporters or survival readouts.
RNA Sequencing (RNA-seq)
Transcriptomic profiling reveals changes in gene expression downstream of PI3K/AKT, such as FOXO targets or metabolic genes.
Live-Cell Imaging
Fluorescently tagged AKT or PIP3 biosensors allow real-time visualization of pathway dynamics in living cells.
How CRISPR Can Be Used to Study GO:0051897 positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
Knockout
CRISPR knockout of negative regulators like PTEN or of candidate positive regulators can reveal their role in PI3K/AKT signaling. For example, PTEN knockout leads to constitutive AKT activation.
Point Mutation
Introducing specific point mutations, such as PIK3CA H1047R or AKT1 E17K, via CRISPR knock-in creates isogenic models to study oncogenic activation of the pathway.
Knock-in
Tagged knock-in of AKT or PI3K subunits with fluorescent or affinity tags enables visualization and biochemical analysis of the pathway in native context.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can upregulate genes to test if they positively regulate PI3K/AKT signaling. This is useful for screening candidate activators.
How EDITGENE Supports positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction Research
Researchers studying positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction-related genes often need to determine whether a candidate gene is causally involved in pathway activation. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction research.
Frequently Asked Questions About positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
What is GO:0051897?
GO:0051897 is a Gene Ontology term for any process that activates or increases the frequency, rate or extent of phosphatidylinositol 3-kinase/protein kinase B signal transduction.
What genes are involved in positive regulation of PI3K/AKT signaling?
Key genes include PIK3CA, AKT1, PTEN, mTOR, and growth factor receptors like EGFR and IGFR.
How is PI3K/AKT signaling activated?
It is activated when growth factors bind to receptors, leading to PI3K recruitment, PIP3 generation, and AKT phosphorylation.
What diseases are associated with PI3K/AKT pathway dysregulation?
Cancer, diabetes, cardiovascular disease, and inflammatory conditions are linked to altered PI3K/AKT signaling.
What is the role of PTEN in PI3K/AKT signaling?
PTEN is a lipid phosphatase that negatively regulates the pathway by converting PIP3 back to PIP2, thus opposing positive regulation.
How can I study positive regulation of PI3K/AKT signaling?
Common methods include phospho-AKT Western blotting, CRISPR screens, RNA-seq, and live-cell imaging.
What are CRISPR models for PI3K/AKT research?
Knockout, point mutation knock-in, tagged knock-in, and overexpression models are widely used to dissect pathway components.
Can glycolysis affect PI3K/AKT signaling?
Yes, glycolysis can fuel PI3K signaling, creating a positive feedback loop that enhances T cell immunity.
What is the role of mTOR in this pathway?
mTORC2 phosphorylates AKT to promote full activation, while mTORC1 is a downstream effector of AKT.
How does FGF4 regulate PI3K/AKT in inflammation?
FGF4 ameliorates liver inflammation by reducing M1 macrophage polarization through PI3K/AKT signaling.
Conclusion
GO:0051897, positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction, is a fundamental biological process with broad implications in health and disease. Understanding its mechanisms, key regulators, and disease connections is essential for developing targeted therapies. EDITGENE offers a full suite of CRISPR services to help researchers functionally validate genes involved in this pathway and accelerate discoveries.
References
- 1. Xu K et al.. 2021. Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity.. Science 371(6527):405-410 PMID: 33479154
- 2. Lin J et al.. 2024. FGF4 ameliorates the liver inflammation by reducing M1 macrophage polarization in experimental autoimmune hepatitis.. J Transl Med 22(1):717 PMID: 39095789
- 3. Ma J et al.. 2025. Inhibition of PI3K/AKT/GLUT1 Signaling Pathway by Quercetin in the Treatment of Psoriasis.. Front Biosci (Landmark Ed) 30(2):26884 PMID: 40018935
- 4. Alsereidi FR et al.. 2024. Dapagliflozin mitigates cellular stress and inflammation through PI3K/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived β cells.. Cardiovasc Diabetol 23(1):388 PMID: 39472869
- 5. Kotelevets L et al.. 2018. Targeting PTEN in Colorectal Cancers.. Adv Exp Med Biol 1110:55-73 PMID: 30623366
- 6. Zhang ZY et al.. 2024. Regulation of optimized new Shengmai powder on cardiomyocyte apoptosis and ferroptosis in ischemic heart failure rats: The mediating role of phosphatidylinositol-3-kinase/protein kinase B/tumor protein 53 signaling pathway.. J Ethnopharmacol 330:118264 PMID: 38692417
- 7. Song K et al.. 2025. Roux-en-Y gastric bypass improves liver and glucose homeostasis in Zucker diabetic fatty rats by upregulating hepatic trefoil factor family 3 and activating the phosphatidylinositol 3-kinase/protein kinase B pathway.. Surg Obes Relat Dis 21(7):792-805 PMID: 39893149
- 8. Zhang SQ et al.. 2002. Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2.. Mol Cell Biol 22(12):4062-72 PMID: 12024020
